Planning Your Treatment
Another study suggests that lumpectomy plus radiation may offer survival benefits for some women diagnosed with early-stage disease.
A study has found that women diagnosed with inflammatory breast cancer who are treated with chemotherapy, surgery, and radiation have better survival rates than women who don't receive all three treatments.
A new study shows that Arimidex and Aromasin are equally good at reducing the risk of recurrence in postmenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer.
A study suggests that women diagnosed with stage I or stage II breast cancer who have lumpectomy followed by radiation have better survival rates than women who have mastectomy alone or mastectomy plus radiation.
Taking tamoxifen for 2 years after surgery offers long-term survival benefits for premenopausal women diagnosed with early-stage, estrogen-receptor-positive disease compared to no treatment after surgery.
A study suggests that if cancer is found in the sentinel lymph node, axillary radiation reduces recurrence risk about the same amount as axillary surgery; axillary radiation also causes less lymphedema than axillary surgery.
Taking Arimidex for 3 years after 5 years of tamoxifen reduced the risk of the cancer coming back in women diagnosed with hormone-receptor-positive breast cancer.
A study has found that young women who wait longer than 6 weeks to have breast cancer surgery have worse survival than young women who have surgery earlier.
U.S. legislators are considering two bills -- one on minimum hospital stays after breast cancer surgery and one on federal funding for environmental links to breast cancer -- that may have a big effect on women diagnosed with the disease.
A small study has found that most younger women diagnosed with early-stage breast cancer who decide to have the other healthy breast removed choose the surgery because they want to reduce their risk of breast cancer developing in the other breast and improve their survival, even though most of them know that removing the other healthy breast doesn't really improve survival rates in women without an abnormal breast cancer gene.
A study suggests that mastectomy followed by reconstruction causes more complications and costs more than the other surgery options for early-stage disease. But that doesn't mean it's not a good option for some women.
Hormone receptor-positive breast cancer survival rates have increased faster than survival rates for hormone receptor-negative breast cancer.
A study found that nearly 25% of women who had lumpectomy had to have more surgery after the pathology report was available.
Another large study finds 10 years of tamoxifen are better than 5.
Research shows that considering a woman's breast cancer risk profile and the specific details of the breast cancer can help doctors figure out which women get the most benefit from prophylactic mastectomy.
Adding the local anesthetic lidocaine (a numbing medicine) to the tracer liquid used in sentinel lymph node biopsy can reduce pain during and after the injection. The lidocaine causes few side effects and doesn't interfere with the procedure's success.
Ultrasound of underarm lymph nodes can determine if cancer has spread to those lymph nodes in some cases.
Breast MRI before breast cancer surgery doesn't lower the risk of the cancer coming back, either in the breast area or in a part of the body away from the breast.
New guidelines on protectively removing both ovaries and the fallopian tubes address the role this surgery can play in reducing the risk of both ovarian and breast cancer.
ASCO has put out new guidelines on using biomarkers to make decisions about treatments after surgery for women diagnosed with early-stage invasive breast cancer.
New research suggests that doing MRI before a first breast cancer surgery doesn't reduce the likelihood that a woman would need more surgery within 6 months.
Switching to an aromatase inhibitor after two to three years of tamoxifen offers improved survival compared to five years of tamoxifen for post-menopausal women with hormone-receptor-positive, early-stage breast cancer.
A study suggests that most women who have contralateral prophylactic mastectomy have no regrets and would make the same choice again.
Women who have contralateral prophylactic mastectomy are slightly more satisfied with how their breasts look and feel compared to women who have single mastectomy, but having reconstruction after breast cancer surgery has a bigger effect on satisfaction.